cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson’s disease

  • S. Mandel
  • E. Grünblatt
  • M. Youdim
Conference paper


cDNA microarray membranes comprising 1,200 different gene fragments have been employed to identify gene expression profile in MPTPinduced nigro striatal dopamine neurodegeneration and its protection with R-apomorphine. Both MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and R-apomorphine (R-APO) induced alterations in specific patterns of gene expression. MPTP altered the expression of 49 different genes involved in oxidative stress (oxidative stress-induced protein A 170, cytochrome P450 1A1 and Osp94), inflammation (cytotoxic cytokines, eg: IL-1, IL-6, TNFalpha), protective cytokines (IL-10), glutamate receptors (NMDA but not AMPA receptors), neurotrophic factors (GDNF, EGF), nitric oxide synthase and transferrin receptor, as determined by microarray membrane hybridization. Furthermore, an additional cascade of further, yet undefined events, also occurred (cell cycle regulators and signal transduction factors), that might act in parallel to oxidative stress (OS) and inflammation, to converge eventually into a common pathway leading to neurodegeneration. R-APO, previously shown by us to protect against MPTP neurotoxicity, prevented the over expression of several genes known to participate in cell death. cDNA microarrays will provide new prospects to study and identify various mechanism of neurodegeneration and neuroprotection not feasible with conventional biochemical procedures, as well as new prospects to develop effective neuroprotective drugs.


MPTP Treated Mouse Dopaminergic Neurodegeneration MPTP Model Signal Transduction Factor MPTP Neurotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bessler H, Djaldetti R, Salman H, Bergman M, Djaldetti M (1999) IL-1ß, IL-2, IL-6 and TNF-a production by peripheral blood mononuclear cells from patients with Parkinson’s disease. Biomed Pharmacother 53: 141–145PubMedCrossRefGoogle Scholar
  2. Cadet JL, Katz M, Jackson-Lewis V, Fahn S (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476: 10–15PubMedCrossRefGoogle Scholar
  3. Debouck C, Goodfellow PN (1999) DNA microarrays in drug discovery and development. Nat Genet Suppl 21: 48–50CrossRefGoogle Scholar
  4. Gassen M, Gross A, Youdim MBH (1998) Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6hydroxydopamine. Mov Disord 13: 242–248PubMedCrossRefGoogle Scholar
  5. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 793: 793–807Google Scholar
  6. Gr¨¹nblatt E, Mandel S, Berkuzki T, Youdim MBH (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 14: 612–618CrossRefGoogle Scholar
  7. Gr¨¹nblatt E, Mandel S, Maor G, Youdim MBH (2000a) Gene expression analysis in MPTP model of Parkinson’s disease using cDNA microarray. Submitted to J NeurosciGoogle Scholar
  8. Gr¨¹nblatt E, Mandel S, Maor G, Youdim MBH (2000b) Alterations of oxidative-stress and inflammatory gene expression in MPTP-induced neurotoxicity and their prevention by R-apomorphine. Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 11–15, 2000Google Scholar
  9. Hadjiconstantinou M, Fitkin JG, Dalia A, Neff NH (1991) Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine-treated mouse. J Neurochem 57: 479–482PubMedCrossRefGoogle Scholar
  10. Hunot S, Brugg B, Richard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-KB is increased in dopaminergic neurons of patients with Parkinson’s disease. Proc Natl Acad Sci USA 94: 7531–7536PubMedCrossRefGoogle Scholar
  11. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson’s and Alzheimer’s disease. J Neural Transm [PD-Sect] 2: 327–340CrossRefGoogle Scholar
  12. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47: 161–170CrossRefGoogle Scholar
  13. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130–1132PubMedCrossRefGoogle Scholar
  14. Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H (1997) Role of iron in NFKB activation and cytokines gene expression by rat hepatic macrophages. Am J Physiol 272: G1355–G1364PubMedGoogle Scholar
  15. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1(3, IL-2, IL-4, IL-6 and transforming growth factor-a levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonian and Parkinson’s disease. Neurosci Lett 211: 13–16PubMedCrossRefGoogle Scholar
  16. Santos BC, Chevaile A, Kojima R, Gullans SR (1998) Characterization of the Hsp110/ SSE gene family response to hyperosmolarity and other stresses. Am J Physiol 274: F1054–F1061PubMedGoogle Scholar
  17. Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the reactivation of the NF-kappa B transcription factor and HIV-1. EMBO J 10: 2247–2258PubMedGoogle Scholar
  18. Youdim MB, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson’s disease [published erratum appears in Mov Disord 1993 Apr;8(2):255]. Mov Disord 8: 1–12CrossRefGoogle Scholar
  19. Youdim MB, Grunblatt E, Mandel S (1999) The pivotal role of iron in NF-B activation and nigro-striatal dopaminergic neurodegeneration; prospects for neuroprotection in Parkinson’s Disease with iron chelators. Ann NY Acad Sci 890: 7–25PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2000

Authors and Affiliations

  • S. Mandel
    • 1
  • E. Grünblatt
    • 1
  • M. Youdim
    • 1
  1. 1.Department of Pharmacology, Eve Topf and US National Parkinson’s Foundation Centers for Neurodegenerative DiseasesBruce Rappaport Family Research Institute Technion — Faculty of MedicineHaifaIsrael

Personalised recommendations